Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Add as a preferred source on Google
LEXINGTON, Mass., April 24, 2017 -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2017 first quarter financial and operational results after the market closes on Tuesday, May 2, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, May 2, 2017, to discuss the financial results and other business developments.
Interested parties may access the live call via telephone by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events & Presentations section of the website.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida® Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.
Media Contact: Matthew McKillip, T2 Biosystems [email protected] 518-577-3466 Investor Contact: Tucker Elcock, Teneo Strategy [email protected] 212-886-9319
